Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Provide Intradigm with siRNA in Drug Discovery Collaboration

NEW YORK, July 8 - Qiagen and Intradigm will collaborate in siRNA drug discovery research & development projects, the companies said today.


Under the agreement, Qiagen will manufacture the siRNA (short interfering RNA), which it will provide to Intradigm for research in oncology, arthritis, and SARS.


For the SARS coronavirus project, Intradigm will design at least 48 sets of siRNA oligos for delivery through the airways, as a potential treatment for the pulmonary infection caused by the virus. The company said it will conduct this project with collaborators at the National Institute of Allergy and Infectious Diseases, as well as ones in Hong Kong and Guangzhou,China


The companies did not disclose the financial terms of the agreement.


Qiagen, of Venlo, the Netherlands, manufactures siRNA for gene silencing using its TOM-Amidite chemistry. The company is one of four companies licensed to supply siRNA under a group of patent applications held by MIT, the Whitehead Institute, the Max Planck Institute, and the University of Massachusetts Medical School.


Intradigm, of Rockville, Md., has developed methods of delivering siRNA in animals, and has conducted studies to validate particular siRNA agents for cancer and viral infection.


SiRNA consists of a short double-stranded sequence of RNA that is delivered into a cell, which triggers the destruction of the mRNA from a target gene.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more